Wanchunbulin and Hengrui Pharmaceuticals reached a strategic cooperation on the commercialization, clinical development and equity investment of punabulin in Greater China

On August 26, Dalian Wanchunbulin Pharmaceutical Co.
, Ltd.
(hereinafter referred to as “Wanchunbulin”) and Jiangsu Hengrui Pharmaceutical Co.
, Ltd.
(hereinafter referred to as “Hengrui Pharmaceutical”) jointly announced the core varieties of Wanchunbulin The exclusive commercialization, clinical development, and equity investment of First in Class's new drug, prenabulin, reached a major strategic cooperation in the Greater China region
.

Pranabrin is a new type of immune antineoplastic drug, which has reached the NDA declaration stage
.

In September 2020, Pranabrin obtained the dual certification of "Breakthrough Therapy Product" by the Chinese and U.

Immunization prevention

The main content and terms of the cooperation:

Main contents and terms of cooperation : Main contents and terms of cooperation:

1.
Commercial cooperation :

1.
Commercialization cooperation 1.
Commercialization cooperation

oCommercialization rights: Wanchunbulin grants Hengrui Pharmaceutical the exclusive commercialization rights for punabulin in the Greater China region; Wanchunbulin will provide Hengrui medicine to Hengrui based on quarterly net sales data after receiving the sales return.
Swiss Medicine pays commercialization costs, and the specific commercialization costs shall be separately agreed by both parties
.

o 

o Development registration and sales milestone payment: After the contract is signed, Hengrui Pharmaceuticals will pay Wanchunbulin down payment plus milestone fees to a total of no more than 1.
3 billion yuan, of which a one-time payment of Wanchunbulin down payment of 200 million yuan, and Upon reaching the corresponding R&D milestones and commercialization milestones, Wanchun Bulin shall pay a total fee of not more than RMB 1.
1 billion
.

2.
Clinical research and development:

2.
Clinical research and development: 2.
Clinical research and development:

oThe clinical development of Pranabrin has been carried out and completed (including Pranabrin combined with docetaxel in the treatment of second and third-line patients with non-small cell lung cancer, and Pranabrin combined with G-CSF drugs to prevent CIN) by Wanchun Brin is responsible, and Wanchun Brin bears 100% of the corresponding R&D expenses
.

o 

o The two parties agree that the follow-up research and development of Punabulin in Greater China will be carried out jointly by both parties, and both parties will pay 50% of the research costs
.

3.
Equity investment: 

3.
Equity investment: 3.
Equity investment:

o Hengrui Medicine subscribed for the shares of Wanchunbulin for RMB 100 million.
After Wanchunbulin completed this round of financing, Hengrui Medicine held no less than 2.
5% of its shares
.

Wanchun Bulin was valued at 3.

Dr.
Huang Lan, co-founder and executive director of Wanchun Bulin, said: “Hengrui Medicine is a leading Chinese oncology drug company with excellent comprehensive commercialization capabilities.
It has worked in the oncology field for more than 40 years.
I am very happy to reach a strategic cooperation with Hengrui Medicine.

In the Chinese market, Hengrui Medicine’s PD-1 antibody and docetaxel products rank first in sales, and G-CSF products are in the top three sales
.

Pranabrin combined with these drugs is expected to achieve an increase in sales .
Effectiveness attenuation

“It’s worth emphasizing that Pranabrin is a cornerstone immuno-oncology drug with greater therapeutic potential
.

Both of us are actively exploring the potential combination of Hengrui’s innovative product lines such as Pranabrin + PD-1 antibody to create differentiation.

Zhang Lianshan, President of Hengrui Pharmaceuticals Global R&D, said: “The treatment and prevention of hematological toxic diseases caused by chemotherapy still represents a huge unmet clinical need.
We very much approve of Pranabrin's ability to prevent neutropenia caused by chemotherapy.
The obvious curative effect
.

Pranabrin has shown very encouraging results in the phase III trial of combined docetaxel in the treatment of second and third-line patients with non-small cell lung cancer.

About Wanchun Bulin

About Wanchunbrin About Wanchunbrin

Wanchun Bulin is a First in Class original innovative drug company based in China and looking at the world.
It is its mission to meet the clinical needs of patients, and is committed to the research and development and commercialization of the first innovative drugs in cancer and other therapeutic fields
.

The company adheres to the core driving force of innovative technologies and products, and continues to develop innovative product portfolios with independent independent intellectual property rights by creating independent innovative R&D platforms and core technologies, so as to benefit more Chinese and global patients

About Hengrui Medicine

About Hengrui MedicineAbout Hengrui Medicine

Founded in 1970, Hengrui Medicine is a national pharmaceutical company engaged in the development and promotion of innovative and high-quality drugs.
It has developed into a well-known domestic supplier of anti-tumor drugs, surgical drugs and imaging intervention products
.

Hengrui has been on the list for 3 consecutive years in the 2021 global pharmaceutical company TOP50 list published by the American Pharmaceutical Manager Magazine, and the ranking has climbed to 38th place year by year; the company has been selected as one of the top 100 companies in China's pharmaceutical industry for many years.

About Punabulin

About Punabulin About Punabulin

Pranabrin is a new synthetic chemical entity.
As a "First in Class" immune anti-tumor drug, Pranabrin can accelerate the immune defense protein guanine nucleotide exchange factor (GEF-H1) Dendritic cells (DC cells) mature and promote antigen presentation, directly activate T cells to kill tumor cells, and act as the "ignition agent of the immune system"
.

In addition, Pranabrin can also promote the maturation of hematopoietic stem and progenitor cells (HSPC) in the bone marrow, prevent chemotherapy damage to the bone marrow, and also shows excellent clinical efficacy in the protection of neutrophils

Stem Cell ASCO

 

Leave a message here